Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

• Main Authors: Praditpornsilpa K., Tiranathanagul K., Kupatawintu P., Jootar S., Intragumtornchai T., Tungsanga K., Teerapornlertratt T., Lumlertkul D., Townamchai N., Susantitaphong P., Katavetin P., Kanjanabuch T., Avihingsanon Y., Eiam-Ong S.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79958824101&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/43043
• Institution: Chiang Mai University

Recombinant human erythropoietin (r-HuEpo) has been used for the treatment of renal anemia. With the loss of its patent protection, there has been an upsurge of more affordable biosimilar agents, increasing patient access to treatment for these conditions. The complexity of the manufacturing process...